[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"burden","before":"\"~330,000 cases per year; incidence rising in fair-skinned populations.\"","after":"\"Melanoma causes about 330,000 cases per year, and incidence is rising in fair-skinned populations.\""}]},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Stage II-III\", approach: \"Adjuvant pembrolizumab/nivolumab; neoadjuvant IO for resectable stage III.\", refs: [\"pembrolizumab\", \"nivolumab\", \"sentinel-node\"] },\n      { setting: \"Metastatic first li...","after":"[\n      { setting: \"Stage II-III\", approach: \"Adjuvant pembrolizumab/nivolumab; neoadjuvant IO for resectable stage III.\", refs: [\"pembrolizumab\", \"nivolumab\", \"sentinel-node\"], guideline: { version: \"NCCN Guidelines:..."}]},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/cancers.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"group"},{"field":"wikipedia"},{"field":"burden"},{"field":"tldr"},{"field":"summary"},{"field":"biomarkers"},{"field":"standardOfCare"},{"field":"stateOfArt"},{"field":"history"},{"field":"pipeline"},{"field":"openProblems"},{"field":"targets"},{"field":"technologies"},{"field":"pathways"},{"field":"tags"}]}]